HENRY SCHEIN INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $HSIC in the last 7 days.
No SEC Form 4 filings for $HSIC in the last 30 days.
See all $HSIC insider activity →Henry Schein (HSIC) reported Q2 revenues of $3.46B, up 6.7% YoY, beating estimates. Envista (NVST) saw 7.1% YoY growth, while Align Tech (ALGN) and Dentsply Sirona (XRAY) reported mixed results. Sector stocks are down 18.3% on average since earnings.
Analysts updated ratings for Nektar Therapeutics (NKTR), Roche Holding AG (RHHVF), and Henry Schein (HSIC). UBS gave NKTR a Hold rating with a $53 target; consensus is $132.70. Jefferies maintained a Sell on RHHVF with a CHF250 target; consensus is $444.60. Leerink Partners kept a Hold on HSIC with a $89 target; consensus is $101.23.
Henry Schein, Inc.'s average price target was reduced by analysts from $99.64 to $97.27, with a range of $64 to $110. This suggests a 16% upside from the Oct. 9 closing price. The consensus rating remains 'Buy' among 19 analysts.
Recent HSIC coverage spans earnings, financial news and corporate actions.
No new catalyst; stock already down 18% since earnings, likely further pressure.
Positive bias from a price target above current levels.
Target cut signals reduced upside expectations, likely pressuring the stock lower.
The leadership change introduces uncertainty ahead of the November earnings release.
New CFO appointment may be viewed as a positive leadership change.
AlphAI scores every news story that mentions HSIC with an AI model for sentiment and relevance, and aggregates insider trades from HENRY SCHEIN INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Henry Schein (HSIC) reported Q2 revenues of $3.46B, up 6.7% YoY, beating estimates. Envista (NVST) saw 7.1% YoY growth, while Align Tech (ALGN) and Dentsply Sirona (XRAY) reported mixed results. Sector stocks are down 18.3% on average since earnings.
3 min readAnalysts updated ratings for Nektar Therapeutics (NKTR), Roche Holding AG (RHHVF), and Henry Schein (HSIC). UBS gave NKTR a Hold rating with a $53 target; consensus is $132.70. Jefferies maintained a Sell on RHHVF with a CHF250 target; consensus is $444.60. Leerink Partners kept a Hold on HSIC with a $89 target; consensus is $101.23.
2 min readHenry Schein, Inc.'s average price target was reduced by analysts from $99.64 to $97.27, with a range of $64 to $110. This suggests a 16% upside from the Oct. 9 closing price. The consensus rating remains 'Buy' among 19 analysts.
1 min readHenry Schein's stock fell 2.5% in pre-market trading after announcing a CFO change. Emmanuel Caprais will replace Ronald N. South, who has served for 18 years, effective November 4, 2026. The company's next earnings report is scheduled for November 3, 2026. Bank of America maintained a Buy rating and $110 price target. The stock is down 6.9% over the past month, trading at $81.56 in pre-market.
2 min readHenry Schein (HSIC) announced Emmanuel Caprais, former CFO of ITT, will join as its CFO on November 4, 2026. He will start as a senior financial advisor on October 12, 2026, to facilitate the transition.
1 min readHENRY SCHEIN INC (HSIC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Henry Schein Announces Chief Financial Officer Leadership Transition • Emmanuel Caprais, former Senior Vice President and CFO of ITT, Inc., to become Henry Schein’s CFO effective November 4, 2026. Mr. Caprais will join the Company in an advisory capacity beginning Oc
2 min readEnvista, Henry Schein, Align Technology, and Dentsply Sirona reported Q2 earnings. Henry Schein beat revenue and EPS estimates, while Align met revenue expectations but missed guidance. Dentsply Sirona's revenue declined but topped estimates. Stocks reacted negatively post-earnings, with Align down 20.1% and Dentsply down 30.6%.
2 min readEnvista (NYSE:NVST) reported Q2 revenue of $730.5M, up 7.1% YoY, beating estimates. Align Technology (NASDAQ:ALGN) reported $1.06B, up 4.3% YoY, missing revenue guidance. Henry Schein (NASDAQ:HSIC) reported $3.46B, up 6.7% YoY, beating estimates. Stocks are down since reporting.
3 min readA former credit supervisor, Tony Ream, was sentenced to 2.5 years in prison for embezzling $1.6M from Henry Schein, a Melville-based medical supplier. Ream used the funds for personal expenses and a failed business venture, according to U.S. Attorney Joseph Nocella.
1 min readHENRY SCHEIN INC (HSIC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Fourth Amended and Restated Revolving Credit Facility On September 21, 2026, the Company amended and restated its existing $1 billion revolving credit agreement, dated as of June 6, 2025, by and among the Company, the several
1 min read
